A New HIV Vaccine Heads to Clinical Trials by Moderna's mRNA Technology

Authors

  • Jyoti Prakash Sahoo Dept. of Agricultural Biotechnology, College of Agriculture, Odisha University of Agriculture and Technology, Bhubaneswar, Odisha (751 003), India
  • Pratikshya Mishra Dept. of Plant Breeding and Genetics, College of Agriculture, Odisha University of Agriculture and Technology, Bhubaneswar, Odisha (751 003), India
  • Kailash Chandra Samal Dept. of Agricultural Biotechnology, College of Agriculture, Odisha University of Agriculture and Technology, Bhubaneswar, Odisha (751 003), India

Keywords:

HIV-AIDS, Moderna, mRNA, Vaccine

Abstract

Moderna, a Massachusetts-based company which has recently been acknowledged for developing a viable COVID-19 vaccine, will soon begin human trials of a revolutionary HIV vaccine. Researchers expect that the mRNA technology used to develop the COVID-19 vaccine will also work against HIV resulting in an effective vaccine against the later. Moderna's strategy is based on the International AIDS Vaccine Initiative, a non-profit organisation and Scripps Research, a non-profit research facility in San Diego. In addition, a collaborative study shown that it is possible to increase activity of immune cells termed germline B-cells, which can create broadly neutralising antibodies against HIV in humans.

Downloads

Download data is not yet available.
Biotica Research Today Vol 3 Issue 10 Cover Page

Downloads

Published

2021-10-09

How to Cite

[1]
Sahoo, J.P. et al. 2021. A New HIV Vaccine Heads to Clinical Trials by Moderna’s mRNA Technology. Biotica Research Today. 3, 10 (Oct. 2021), 853–856.

Issue

Vol. 3 No. 10 (2021): October, 2021

Section

General Article

Most read articles by the same author(s)

1 2 3 4 5 6 > >>